R3HDM2

Across TCGA pan-cancer cohorts, R3HDM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated R3HDM2 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher R3HDM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated R3HDM2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

LUAD, GBM, and HNSC are the cancer types where R3HDM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.469	0.823	<.001	44	view →
GBM	DFS	Median	All	0.793	0.649	.001	19	view →
HNSC	DFS	Median	All	1.000	0.921	.007	12	view →
CCRCC	DFS	Tertile	II,III,IV	0.865	0.385	.009	8	view →
LSCC	DFS	Median	II,III,IV	1.000	0.571	.030	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

R3HDM2–LUAD (DFS)

Open the LUAD breakdown →